Rigel(RIGL) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Rigel Reports First Quarter 2024 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., May 7, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2024, including sales of TAVALISSE (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment and sales of REZLIDHIA(olutasidenib) ...